Genome-wide expression profiling of the response to terbinafine in Candida albicans using a cDNA microarray analysis

Chinese Medical Journal

Volumn 120, Issue 9, 2007, Pages 807-813

  Zheng, Yue Bin ^a   Qian, Yuan Shu ^a   Ma, Lian ^a   Gu, Hong Ni ^a  

^a SHANTOU UNIVERSITY MEDICAL COLLEGE   (China)

Author keywords

Candida albicans; Efflux pumps; Gene regulation; Microarrays; Terbinafine

Indexed keywords

ABC TRANSPORTER; PROTEIN AGP 2; PROTEIN CDR 1; PROTEIN ERG 1; PROTEIN FCY 23; PROTEIN GAP 6; PROTEIN HOL 3; PROTEIN PHO 84; PROTEIN VCX 1; TERBINAFINE; UNCLASSIFIED DRUG;

ARTICLE; CANDIDA ALBICANS; CELLULAR STRESS RESPONSE; CONTROLLED STUDY; DETOXIFICATION; DNA MICROARRAY; DOWN REGULATION; FUNGAL GENE; FUNGAL STRAIN; GENE EXPRESSION; GENE EXPRESSION PROFILING; MINIMUM INHIBITORY CONCENTRATION; MULTIDRUG RESISTANCE; NONHUMAN; OPEN READING FRAME; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA ISOLATION; UPREGULATION;

EID: 34248638230     PISSN: 03666999     EISSN: None     Source Type: Journal    
DOI: 10.1097/00029330-200705010-00013     Document Type: Article

References (24)

1. Wu S, Liao W, Guo N, Chinese Collaborative Fungi Research Group. Epidemiological study of pathogenic fungi in China: 1986 and 1996. Chin Med J 2001; 114:294-296.
2. Balfour JA, Faulds D. Terbinafine: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in superficial mycoses. Drugs 1992; 43:259-284.
3. Ryder NS, Mieth H. Allylamine antifungal drugs. Curr Top Med Mycol 1992; 4:158-188.
4. Jung EG; Haas PJ, Brautigam M, Weidinger G. Systemic treatment of skin candidosis: a randomized comparison of terbinafine and ketoconazole. Mycoses 1994; 37:361-365.
5. Nolting S, Brautigam M, Weidinger G. Terbinafine in onychomycosis with involvement by non-dermatophytic fungi. Br J Dermatol 1994; 130(Suppl 43): 16-21.
6. Ryder NS. Terbinafine: mode of action and properties of the squalene epoxidase inhibition. Br J Dermatol 1992; 126 Suppl 39: 2-7.
7. Lockhart DJ, Winzeler EA. Genomics, gene expression and DNA arrays. Nature 2000; 405:827-836.
8. Bammert GF, Fostel JM. Genome-wide expression patterns in Saccharomyces cerevisiae: comparison of drug treatments and genetic alterations affecting biosynthesis of ergosterol. Antimicrob Agents Chemother 2000; 44: 1255-1265.
9. De Backer MD, Ilyina T, Ma XJ, Vandoninck S, Luyten WH, Vanden Bossche H. Genomic profiling of the response of Candida albicans to itraconazole treatment using a DNA microarray. Antimicrob Agents Chemother 2001; 45:1660-1670.
10. Zhang L, Zhang Y, Zhou Y, An S, Zhou Y, Cheng J. Response of gene expression in Saccharomyces cerevisiae to amphotericin B and nystatin measured by microarrays. J Antimicrob Chemother 2002; 49:905-915.
11. Zhang L, Zhang Y, Zhou Y, Zhao Y, Zhou Y, Cheng J. Expression profiling of the response of Saccharomyces carevisiae to 5-fluorocytosine using a DNA microarray. Int J Antimicrob Agents 2002; 20; 444-450.
12. National Committee for Clinical Laboratory standards. Reference method for broth dilution antifungal susceptibility testing of yeasts: Approved standard. Wayne, PA, USA: NCCLS. 1997.
13. Franz R, Kelly, M27-A, Vol.17, No.9 SL, Lamb DC, Kelly DE, Ruhnke M, Morschhauser J. Multiple molecular mechanisms contribute to a stepwise development of fluconazole resistance in clinical Candida albicans strains. Antimicrob Agents Chemother 1998; 42:3065-3072.
14. Chau AS, Mendrick CA, Sabatelli FJ, Loebenberg D, McNicholas PM. Application of real-time quantiitative PCR to molecular analysis of Candida albicans strains exhibiting reduced susceptibility to azoles. Antimicrob Agents Chemother 2004; 48:2124-2131.
15. White TC, Holleman S, Dy F, Mirels LF, Steven, DA. Resistance mechanisms in clinical isolates of Candida albicans. Antimicrob Agents Chemother 2002; 46:1704-1713.
16. Sanglard D, Ischer F, Calabrese D, Majcherczyk PA, Bille J. The ATP binding cassette transporter gene CgCDR1 from Candida gldbrata is involved in the resistance of clinical isolates to azole antifungal agents. Antimicrob Agents Chemother 1999; 43:2753-2765.
17. Franz R, Ruhnke M, Morschhauser J. Molecular aspects of fluconazole resistance development in Candida albicans. Mycoses 1999; 42:453-458.
18. Franz R, Kelly SL, Lamb DC, Kelly DE, Ruhnke M, Morschhauser J. Multiple molecular mechanisms contribute to a stepwise development of fluconazole resistance in clinical Candida albicans strains. Antimicrob Agents Chemother 1998; 42:3065-3072.
19. Rogers PD, Barker KS. Evaluation of differential gene expression in fluconazole-susceptible and -resistant isolates of Candida albicans using cDNA microarray analysis. Antimicrob Agents Chemother 2002; 46:3412-3417.
20. Rogers PD, Barka KS. Genome-wide expression profile analysis reveals coordinately regulated genes associated with stepwise acquisition of azole resistance in Candida albicans clinical isolates, Antimicrob Agents Chemother 2003; 47:1220-1227.
21. Lee RB, Liu TT, Barker KS, Lee R, Rogers PD. Genome-wide expression profiling of the response to ciclopirox olamine in Candida albicans. J Antimicrob Chemother 2005; 55:655-662.
22. Daum G, Lees ND, Bard M, Dickson R. Biochemistry, cell biology and molecular biology of lipids of Saccharomyces cerevisiae. Yeast 1998; 14:1471-1510.
23. Oulmouden A, Karst F. Isolation of the ERG12 gene of Saccharomyces cerevisiae encoding mevalonate kinase. Gene 1990; 88:253-257.
24. Beilharz TH, Preiss, T. Translational profiling: the genome-wide measure of the nascent proteome. Brief Funct Genomic Proteomic 2004; 3:103-111.